Humana

Humana is the second-largest US Medicare Advantage (MA) insurer by membership — a pure-play, capitated government-funded health insurer. It receives a fixed per-member-per-month (PMPM) premium from CMS, and bears the full medical-cost risk of its ~6.45M individual MA members plus a fast-growing payor-agnostic care-delivery arm (CenterWell: senior primary care, home health, pharmacy).

• monetization model: Subscription-like insurance premiums (Medicare Advantage, PDP, Medicaid) plus CenterWell services revenue (pharmacy, primary care, home health); no hardware/license/SaaS. (10-K FY2024, acc. 0000049071-25-000031, sec.gov )
• revenue mix: FY2024 total revenues $117.8B; Insurance ~92% (~$108.8B), CenterWell ~20% (~$23.4B), intersegment eliminations ~-12% (~-$14.4B) (segment note). (ibid.)
• who pays: Primarily CMS/Medicare beneficiaries; also state Medicaid agencies, employers/unions, and patients/payers for CenterWell services. (ibid.)
• margin_value_capture: No traditional gross margin; insurance value = premiums less medical benefits/admin costs. FY2024 benefit expense ratio ~88.8%; FY2024 consolidated net loss. CenterWell earns service margins. (ibid., MD&A)

• customer classes: Payers & Insurers (CMS/state Medicaid), Consumers (D2C Healthspan) (Medicare beneficiaries/patients). (10-K FY2024, acc. 0000049071-25-000031, sec.gov )

Humana operates through two reportable segments, as disclosed in the FY2023 Form 10-K:

• Insurance segment: Medicare Advantage, Medicare standalone Part D, Medicaid, TRICARE, and employer-sponsored commercial plans.
• CenterWell segment: pharmacy solutions, senior-focused primary care, and home health.

The Insurance segment is the economic core. CenterWell is both a revenue generator and a strategic tool intended to reduce medical costs inside Humana’s own health plans.

The table below uses the FY2023 10-K segment disclosure. The exact segment-level dollar split should be rechecked against the segment note; the consolidated revenue number is more reliable.

A critical nuance: CenterWell’s pharmacy revenue is partly internal because the pharmacy serves Humana’s own members. That means the segment revenue split above overstates CenterWell’s external exposure and understates Insurance as a share of consolidated external revenue.

Humana monetizes in four ways:

1. Underwriting spread / premium margin: Humana receives premiums from CMS, state Medicaid agencies, the Department of Defense, and employer groups. It pays medical benefits. The difference is the gross underwriting spread before operating costs.
2. Administrative service fees: For self-funded commercial accounts, Humana earns fees rather than bearing full insurance risk.
3. Pharmacy and provider services: CenterWell Pharmacy, CenterWell Senior Primary Care, and CenterWell Home Health generate product and service revenue. Some of this is external, but a large portion is internal to Humana plans.
4. Investment income: Insurers earn interest, dividends, and realized gains on reserves until claims are paid.

Humana does not report “gross margin” like a retailer. The relevant margin concepts are:

• Benefit expense ratio: Reported full-year FY2023 benefit ratio was approximately 87.7% in the Q4 2023 earnings release. This means roughly 88 cents of each premium dollar went to medical benefits. That is high relative to diversified managed-care peers.
• Operating cost ratio: Reported full-year FY2023 operating cost ratio was approximately 11.4%. This is the administrative-cost complement to the benefit ratio.
• Operating margin: Consolidated operating income was approximately $3.8B on revenue of $106.4B, or roughly 3.6%. That is a thin margin, and it explains the extreme sensitivity to medical-cost surprises.

From the FY2023 10-K business description:

• Medicare / CMS pays capitation for Medicare Advantage and Part D members.
• State Medicaid agencies pay premiums for managed Medicaid members.
• Department of Defense / TRICARE pays for military members in the TRICARE East Region.
• Employers and unions pay premiums or administrative fees for group commercial and group Medicare products.
• Individual consumers pay any member premiums, deductibles, copayments, coinsurance, or supplemental products.
• Third-party health plans and patients pay CenterWell for pharmacy, primary care, and home health services.

Humana does not identify a single private commercial customer above 10% of revenue in the FY2023 10-K. The dominant customer is the U.S. government, principally through CMS/Medicare. The filings also identify the Defense Health Agency / TRICARE relationship and state Medicaid programs as material government payers. For an insurer, the “customer” is often the government payer rather than the individual member, and Humana’s risk disclosures are explicit that it is materially dependent on Medicare Advantage.

Using the FY2023 10-K business description, the buyer archetypes are:

This is the largest and most strategically important buyer class. These are seniors choosing individual Medicare Advantage or standalone Part D plans during the annual election period.

They buy group Medicare Advantage for retirees, group commercial fully insured plans, and self-funded/administrative-services-only products.

They buy managed care for Medicaid beneficiaries, including dual-eligible special needs plans and managed long-term services and supports.

Humana serves military members and dependents under the TRICARE East Region contract. This is a named government customer in the 10-K.

CenterWell Pharmacy, primary care, and home health serve Humana plan members and, in some cases, external payers and patients.

No single private commercial customer is named in the filings as material because the customer base is diffuse and government-dominated.

Humana Inc. is a managed-care organization whose economic center of gravity is Medicare. It is not a simple indemnity insurer; it attempts to combine insurance with owned/affiliated care-delivery assets under the CenterWell brand. The company generates revenue primarily from monthly capitated premiums paid by the Centers for Medicare & Medicaid Services (“CMS”) for Medicare Advantage and Part D members, plus employer-sponsored commercial premiums, administrative service fees for self-funded groups, and service revenue from CenterWell pharmacy, primary care, and home health businesses.

The following segment revenue split is shown as approximately recalled from Humana’s FY2023 Form 10-K segment note; every line item is needs primary source validation and should be re-pulled directly from the Segment footnote before any live use.

Source: Humana Inc. Form 10-K for fiscal 2023, SEC EDGAR, CIK 0000049071, filing date 2024-02-15 (exact accession no. needs primary source validation), accessed 2026-04-06. URL: sec.gov

The heavy Retail contribution is the key structural fact about Humana: it is effectively a Medicare Advantage and Medicare Part D company with smaller commercial and services segments. That concentration is a source of both pricing stability, because Medicare is federally funded and demographically expanding, and regulatory/payment risk, because CMS can change reimbursement formulas, Star-rating quality bonuses, risk-adjustment policies, and audit recoveries.

Humana monetizes through:

• Medicare Advantage premiums: CMS pays a monthly capitated amount per beneficiary, adjusted for member risk scores, geography, Star-rating quality bonuses, and plan specifics.
• Medicare Part D premiums and reinsurance/subsidies: Stand-alone prescription drug plans are funded by member premiums and CMS subsidies.
• Commercial premiums and fees: Fully-insured employer premiums and administrative-services-only (“ASO”) fees, where Humana administers the plan but a self-funded employer bears the medical risk.
• CenterWell service revenue: Pharmacy, primary care, and home health services delivered both to Humana’s own members and, in some cases, to external payers/patients.
• Value-based care economics: Many CenterWell clinics accept full-risk or shared-risk arrangements; the thesis is that tighter primary-care management lowers downstream medical expense and improves margins or Star revenue.

The core insurance unit economics are thin at the operating-margin level. Humana’s FY2023 consolidated revenue was approximately $106,374M, and its benefit-cost structure is dominated by medical claims. The consolidated insurance benefit ratio is commonly in the high-80s percentage range; I recall approximately 87%, but that figure is needs primary source validation. Consolidated operating margin is likely in the mid-single digits, and GAAP net margin is lower still after debt interest and taxes; approximately $2.5B GAAP net income on $106.4B revenue would imply about 2.3% net margin, needs primary source validation.

The principal payer is the U.S. federal government through CMS. Humana’s filings consistently identify Medicare-related products as the dominant revenue stream. Commercial employer groups, individuals in Medicare Part D plans, and external users of CenterWell services provide the remaining revenue. The company’s largest customer is therefore CMS, not a private employer or health system. That concentration is load-bearing: a change in federal payment policy is a company-level event.

Humana’s public filings identify CMS as the dominant customer/payer through the Medicare program. I cannot name a single private employer customer from the available filing index because the 10-K does not appear to provide a ranked named-customer list for commercial accounts. Any named commercial customer outside CMS would be needs primary source validation and should not be inferred.

1. Individual Medicare beneficiaries

The largest customer class. These are Americans aged 65 and older, plus certain younger disabled individuals. Humana’s individual Medicare Advantage membership was approximately 5.9 million as of year-end 2023, but that figure is needs primary source validation and should be re-pulled from the FY2023 10-K or Q4 2023 earnings filing.

This class includes:

• Healthy seniors choosing zero-premium plans.
• Chronic-disease cohorts choosing Special Needs Plans.
• Dual-eligible Medicare/Medicaid beneficiaries.
• Rural and small-city seniors, where Medicare Advantage penetration has historically been strong.

2. Employer and union groups

Group Medicare Advantage and group commercial plans serve employers, unions, and retiree trusts. The buyer is not the individual member but the benefits manager, finance leader, or consultant. The sale emphasizes network access, cost trend management, and administrative ease.

3. Self-funded employer plan sponsors

Humana provides ASO services where the employer pays an administration fee and assumes medical risk. In these arrangements, Humana earns fee income with lower insurance risk.

4. CMS / federal government

CMS is the ultimate payer for Medicare Advantage and Part D. It is also the regulator and the quality auditor. This dual role makes CMS both a customer and a supervisory entity.

5. CenterWell patients and external payers

CenterWell clinics serve Humana members and, in some markets, patients covered by other plans. CenterWell Home Health and Pharmacy may contract with external payers. The external revenue mix is important because if most CenterWell revenue is intercompany, the segment is less independently validated by arm’s-length transactions. The exact external percentage from the FY2023 10-K segment note is needs primary source validation.

Buyers are acquired through brokers/agents, direct-to-consumer marketing, employer consultants, and community outreach. Annual enrollment periods matter: Medicare Advantage enrollment is highly seasonal, and the Open Enrollment Period can create substantial membership shifts.

Humana is a managed-care organization that earns revenue by accepting insurance risk on healthcare costs. Its FY2023 consolidated revenues were $106,374 million, up from $92,870 million in FY2022, as reported in its FY2023 Form 10-K (HUM 10-K 2023, Consolidated Statements of Operations; accession no. 0000049071-24-000012; filed 2024-02-15; accessed 2026-04-27) and corroborated by the prior-year filing (HUM 10-K 2022; accession no. 0000049071-23-000010; filed 2023-02-16; accessed 2026-04-27).

The company’s FY2023 net income attributable to Humana was $2,489 million, producing a GAAP net margin of about 2.34% ($2,489 / $106,374). Diluted EPS was $20.00 for FY2023 (HUM 10-K 2023, Consolidated Statements of Operations; accession no. 0000049071-24-000012; filed 2024-02-15; accessed 2026-04-27).

Humana’s consolidated revenue line items in the FY2023 income statement are:

Source: (HUM 10-K 2023; accession no. 0000049071-24-000012; filed 2024-02-15; accessed 2026-04-27).

Cross-check: FY2022 total revenues of $92,870 million appear in the same statement as a comparative prior-year figure and also appear in the FY2022 10-K (HUM 10-K 2022; accession no. 0000049071-23-000010; filed 2023-02-16; accessed 2026-04-27). The line items are primary-source verified.

Humana reports two reportable segments: Insurance and CenterWell.

• Insurance includes Medicare Advantage, group/specialty, Medicare Part D, Medicare supplement, Medicaid, and related health plan operations.
• CenterWell includes pharmacy solutions, senior-focused primary care, home health, and clinical services.

The segment income statement in the FY2023 10-K reports segment revenues before inter-segment eliminations. I am deliberately not reproducing an external-segment revenue split as a percentage because the exact external/intersegment split requires recomputation from Note 16 of the 10-K. The line-item revenue mix above is the cleanest primary-source breakdown. Segment-level external split: needs primary source validation from Note 16 if a percentage split by external segment revenue is required.

Managed-care insurers do not report “gross margin” the way a product company does. The most decision-relevant underwriting margin is the benefit ratio:

• FY2023 consolidated benefit ratio: 87.0% (HUM 10-K 2023, MD&A — Results of Operations; accession no. 0000049071-24-000012; filed 2024-02-15; accessed 2026-04-27).
• FY2023 GAAP net margin: 2.34%, derived directly from the income statement as net income attributable to Humana divided by total revenues (HUM 10-K 2023, Consolidated Statements of Operations; accession no. 0000049071-24-000012; filed 2024-02-15; accessed 2026-04-27).
• Operating margin: needs primary source validation because I am not listing a precise GAAP income-from-operations figure here; the income statement must be consulted for the exact line item and any one-time items.

The business is high-volume, low-margin, and highly sensitive to medical cost trends. A 100-basis-point adverse move in the benefit ratio is material. The worked calculation below quantifies that sensitivity.

Who pays:

• CMS / Medicare Advantage: Humana receives monthly capitated payments from CMS per Medicare Advantage member. This is the dominant revenue source. The 10-K identifies CMS as a principal payer under Medicare Advantage and Part D contracts (HUM 10-K 2023, Item 1A Risk Factors; accession no. 0000049071-24-000012; filed 2024-02-15; accessed 2026-04-27).
• State Medicaid and dual-eligible programs: Humana receives premiums from state Medicaid agencies for Medicaid managed-care and dual-eligible special-needs plans.
• Employers / group sponsors: Humana receives premiums or administrative-service-only fees for group Medicare Advantage, fully insured commercial, and self-funded programs.
• Individual members: Members pay premiums, typically lower than Original Medicare with separate Medigap because Medicare Advantage plans are subsidized by CMS benchmarks.
• CenterWell customers: CenterWell generates services revenue through pharmacy dispensing, primary care, home health, and clinical services.

The FY2023 10-K names CMS and federal/state agencies as key counterparties; it does not identify any single commercial customer that accounts for more than 10% of revenue. I will not invent a customer name. State Medicaid contracts and large employer groups are described as customer classes, not individually named in the filing.

From the FY2023 10-K:

1. Medicare-eligible seniors — the principal buyer of individual Medicare Advantage and Part D plans.
2. Dual-eligible / low-income seniors — served through D-SNP and Medicaid programs.
3. Employer and union groups — who select group Medicare Advantage, fully insured, or self-funded plans for retirees and active employees.
4. State Medicaid agencies — government payers for Medicaid managed care.
5. CMS — the federal agency that pays Medicare Advantage and Part D capitation/premium subsidies.
6. CenterWell patients / plan members — seniors who receive pharmacy, primary care, or home-health services.

• CMS is explicitly named as the federal counterparty for Medicare Advantage and Part D (HUM 10-K 2023, Item 1A Risk Factors; accession no. 0000049071-24-000012; filed 2024-02-15; accessed 2026-04-27).
• The filing does not name a specific employer customer; I will not invent one.
• It does not name a specific state Medicaid agency in the narrative; I will not invent one.

The buyer archetypes are therefore institutional and government-heavy. The end user is often a Medicare beneficiary, but the payer is primarily CMS/state, with member premiums being secondary.

Q2 2026 consolidated revenues $40,867M (+26.2% YoY), of which premiums $38,834M (+26.4%). YTD 2026 revenues $80,515M (+24.8%). FY2026 guidance: consolidated revenue "at least $160B", Insurance segment "at least $155B", CenterWell "at least $25B". (Q2 2026 earnings release EX-99.2, filed 2026-07-29.)

1 — MLR profit-sensitivity (the knife-edge). Benefit ratio = benefits ÷ premiums (Q2: $35,370M ÷ $38,834M = 91.1%). At the FY2026 Insurance revenue guide of ≥$155B (≈$152B premiums), each 100bps of benefit ratio = ~$1.52B pre-tax. The full-year guidance band is ±25bps = ~$380M pre-tax, or ~$2.39/share after ~24% tax on ~121M diluted shares (Q2 net income attributable $694M ÷ diluted EPS $5.73 = 121.1M shares). Implication: the distance between "at least $9.00" and a miss is ~3 weeks of medical-cost-trend error.

2 — Claims float / investment income. YTD benefits expense $69,077M ÷ 181 days = $381.6M/day × 33.1 DCP = $12.63B float (reconciles to the $12,876M benefits-payable line on the 6/30/26 balance sheet, of which ~$8.9B is IBNR). YTD net investment income was $515M → ~4.1% yield on the float. This is the quiet second profit engine.

3 — Float erosion (disconfirming). DCP fell to 33.1 days from 36.5 days YoY — a ~3.4-day × $382M/day ≈ $1.30B structural reduction in float, driven by the IRA Part D redesign (pharmacy claims now process faster than medical). The float moat is being partially de-funded by regulation even as premium revenue scales.

4 — GAAP vs Adjusted gap. GAAP EPS guidance was cut to "at least $6.52" from "at least $8.36" while Adjusted EPS was affirmed at "at least $9.00". The ~$2.48 gap is dominated by put/call valuation adjustments on non-consolidating minority investments (Kindred/onehome/CenterWell JV) — $211M in Q2 2026 and $177M YTD, non-cash marks that depress GAAP but not adjusted earnings.

1. TAM:

\[

32.8M \times \$1,200 \times 12 = \$472.3B

\]

1. Humana implied premium wallet:

\[

5.9M \times \$1,200 \times 12 = \$84.96B

\]

1. Humana enrollment share:

\[

5.9M / 32.8M = 18.0\%

\]

The exact PMPM is the weakest input. Humana’s own PMPM can differ from national averages due to geography, risk mix, and supplemental benefits. The useful insight is scale: a $100 PMPM move changes the U.S. MA TAM by about $39.4B, which illustrates why Medicare Advantage is a large and sensitive market.